Clinical trials are essential to medical progress, offering patients early access to innovative treatments. But for many, the cost of participation creates an invisible wall. Financial barriers—like travel, childcare, unpaid time off, or internet access—can shut out those who need trials the most. These barriers don’t just limit individual opportunity; they skew research by excluding diverse voices. If trials aren’t accessible to all, the data they produce won’t fully represent the population. Addressing this inequity isn’t just fair—it’s critical to reliable science.
Socioeconomic status plays a central role in determining who gets through the door. People from lower-income backgrounds, often facing systemic inequities, are more likely to find trial participation financially out of reach. This is particularly troubling because these same populations frequently bear a greater burden of disease. Closing the gap means confronting financial obstacles head-on and rethinking how we design and support clinical trials. Real change starts when we acknowledge these invisible costs—and act to reduce them.
Researchers and sponsors must recognise that removing financial barriers isn’t just generous—it’s strategic. Compensation for time, travel reimbursements, and logistical support increase both enrolment and retention. More importantly, these measures send a message: every patient’s time and health are valued. Transparent and fair compensation should be standard protocol, not an afterthought. Providing this kind of support turns trials from exclusive opportunities into inclusive solutions.
Beyond individual costs, institutional policies often compound the problem. Participants may lose access to public benefits if reimbursed incorrectly. Lack of coordination between trial organisers and social service systems creates additional stress for patients who already feel vulnerable. It’s vital that trial policies are designed with these realities in mind. Consultation with community organisations, patient advocates, and social workers can help ensure financial support doesn’t create unintended harm.
Tackling Financial Barriers With Smart Trial Design
Trial access is shaped by geography as much as by income. Rural patients often travel long distances to reach study sites, while urban participants may face steep transit costs or inflexible work schedules. Hybrid and decentralised trials can reduce some of these burdens by allowing more activities to take place remotely. But these models aren’t one-size-fits-all. Digital access, tech literacy, and comfort with remote monitoring vary widely. Including patients in trial design helps uncover which formats are practical and where more support is needed.
The connection between socioeconomic disparity and trial participation isn’t abstract. Studies show that people of colour, who are disproportionately affected by poverty, are underrepresented in trials. This results in treatments that may be less effective—or even unsafe—for the very groups most impacted by disease. Closing this gap requires proactive strategies, such as recruiting through trusted community networks and offering flexible compensation structures. It also means confronting biases in trial design, outreach, and eligibility criteria.
Efforts to improve inclusion must include structural changes to funding. Many trials operate under tight budgets that don’t prioritise participant support. But funders and sponsors hold the power to change that. Budgeting for comprehensive financial assistance—including transportation, internet stipends, and caregiver compensation—should be as standard as budgeting for lab tests. Building this into the financial structure of a trial sends a clear signal about whose needs matter.
Reimagining Trial Access Through Inclusive Practices
Patient trust is earned through clarity, respect, and meaningful support. Clear, plain-language materials about what costs are covered, how to access support, and what to expect financially can reduce anxiety and promote participation. Patients should never have to guess whether they’ll be reimbursed—or fear unexpected costs. Open communication builds partnerships that are sustainable and informed, rather than extractive.
The lack of transparency in costs can also impact patient willingness to remain in a study. Unclear reimbursement timelines, confusing policies, or the burden of fronting expenses can all lead to dropout. Addressing these barriers improves not just enrolment, but also retention and data quality. Embedding patient feedback throughout the trial process ensures that solutions stay grounded in lived reality. When patients are invited to co-design financial support strategies, those strategies are more likely to succeed.
Supporting equitable access means taking a hard look at systemic barriers and actively removing them. Financial support isn’t charity—it’s justice. Making clinical trials fair and representative benefits everyone. Stronger data, faster recruitment, and better outcomes are all tied to who can afford to show up. That’s why rethinking financial models is not just a patient advocacy issue—it’s a scientific one.
A Patient-Centred Approach to Trial Access
To move forward, the clinical trial community must embrace an inclusive model grounded in empathy and evidence. Trial design must reflect the real-life circumstances of the people it hopes to serve. Financial support structures must anticipate—not react to—patient needs. And community input must shape every step of the process.
More resources are now available for trial organisers looking to improve trial access. There is no shortage of ideas—only a shortage of will. But the cost of inaction is high: underrepresentation, mistrust, and flawed science. Investing in patient support isn’t a luxury. It’s the foundation of ethical research.
Keith Berelowitz | Founder & CEO
Keith Berelowitz is the Founder of pRxEngage, a company redefining patient engagement and retention in clinical trials using living experience, proven methods, and AI.
